Visão geral da empresa
A clinical stage biotechnology company, Vera Therapeutics, Inc. specializes in the development and commercialization of transformative treatments designed for patients suffering from immunological diseases, with a specific focus on atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF). The firm operates within the healthcare sector, specifically in the biotechnology industry, a domain characterized by high research and development expenditures and significant regulatory hurdles before products reach the market. As of the latest data, the company possesses a market capitalization of $2.88B and employs a workforce of 249 individuals dedicated to its scientific and operational objectives. While the company reports no annual revenue, generating a Price to Sales metric that is effectively N/A, the market cap of $2.88B indicates that the market values the company based on the potential future success of its pipeline rather than current cash generation, which is typical for early-stage biopharmaceutical entities. This valuation suggests that the market is pricing in significant future growth expectations from its drug candidates, despite the absence of commercial sales to date.
Saúde financeira
Vera Therapeutics reports Net Income (TTM) of $-299,615,008 and EBITDA of $-315,004,992, figures that highlight the substantial cash burn inherent in the clinical development phase of a biotechnology firm. The gap between the reported revenue, which is N/A, and the significant net loss reveals a cost structure dominated by research and development expenses rather than cost of goods sold, as the company has not yet achieved commercial scale. The Free Cash Flow stands at $-139,023,504, indicating a consistent outflow of capital required to fund operations and clinical trials, which limits immediate financial flexibility but is a standard operational characteristic for companies in the clinical stage. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, a status that reflects the company's lack of commercial revenue streams and the absence of profit generation from sales. On the balance sheet, the company holds $714.59M in cash against $77.31M in debt, resulting in a Debt to Equity ratio of 12.79, which presents a mixed picture of a highly leveraged ratio metricically, yet one supported by a robust cash hoard that mitigates immediate solvency risk. The Current Ratio is an exceptionally high 13.63, signaling that the company has more than thirteen dollars of current assets for every dollar of current liabilities, suggesting strong short-term liquidity despite the negative cash flow. Furthermore, the Return on Equity is -50.7% and the Return on Assets is -28.4%, metrics that indicate that the company's equity and asset base are currently being utilized to generate losses rather than profits, a common phenomenon for clinical-stage biotechs investing heavily in their pipeline.
Avaliação de valorização
The valuation of Vera Therapeutics presents a unique scenario where the Trailing P/E is N/A due to negative earnings, while the Forward P/E is listed at -13.25, a figure that technically suggests negative earnings growth expectations in the forward model or a data anomaly given the company's lack of revenue. The Price to Book ratio stands at 4.75, indicating that the market is pricing the company at a significant premium of nearly five times its book value, reflecting the high potential value investors assign to its intellectual property and drug candidates. Since revenue is N/A, the Price to Sales ratio is also N/A, and the EV/EBITDA is -7.11, which serves as an alternative valuation metric that further underscores the negative earnings trajectory typical of pre-revenue biotechnology firms. Regarding trading range, the stock has a 52-Week High of $56.05 and a 52-Week Low of $18.53, placing the current trading price somewhere within this wide band, though the exact percentage relative to the high cannot be calculated without the current share price. The Beta is 1.17, which implies that the stock's price volatility is 17% higher than that of the broader market, indicating that investors should expect greater swings in share price relative to a standard benchmark.
Growth & Income
Vera Therapeutics reports Revenue Growth (YoY) and Earnings Growth (YoY) as N/A, reflecting the company's status as a pre-revenue entity with no historical earnings data to compare against. Consequently, there is no dividend yield or payout ratio, as the Dividend Yield is N/A and the Payout Ratio is 0.0%, meaning the company retains all of its capital to fund ongoing research and development rather than distributing income to shareholders. The absence of a dividend policy is consistent with the company's life cycle stage, where reinvestment of funds into clinical trials and manufacturing scale-up is prioritized over shareholder payouts. The overall growth and income profile is defined entirely by the potential future monetization of the atacicept pipeline, as current financial growth metrics are unavailable and income is generated exclusively through equity appreciation rather than dividends or operational profits.